PACB Pacific Biosciences of California Inc.

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time.

The call will be webcast and may be accessed at PacBio’s website at .

Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT)

Listen live via internet or replay:

Toll-free: 1-888-349-0136

International: 1-412-317-0459

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit  and follow @PacBio.  

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.  

Contacts

Investors:

Jim Gibson

Media:



EN
27/01/2026

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Completes Sale of Short-Read Sequencing Assets

PacBio Completes Sale of Short-Read Sequencing Assets MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and gr...

February 2, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results o...

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Plans for Collaboration With n-Lorem Foundation and E...

PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the...

January 12, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenue MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. “We finished the year with strong momentum driven by increas...

January 12, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate S...

PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that a UW Medicine and Seattle Children’s research effort led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, will employ PacBio HiFi who...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch